SEC Says Liquid Staking Safe
The U.S. Securities and Exchange Commission (SEC) clarified Tuesday that liquid staking does not require securities law disclosures, according to a new staff statement. This applies when users deposit crypto assets with a third-party provider who stakes them and issues receipt tokens in return. The guidance, issued by the Division of Corporation Finance, suggests that participants—both depositors and staking providers—can operate without fear of SEC enforcement, provided they follow the outlined framework.
Importantly, the crypto must not be part of an investment contract. Liquid staking allows users to earn staking rewards while still accessing their assets via derivative tokens, widely used in DeFi. With nearly $67 billion locked in liquid staking protocols, including $31.7 billion in Lido, the market is significant. Tokens tied to platforms like Lido, Jito, and Rocket Pool rose slightly after the announcement. While the statement isn't formal rulemaking, it signals the SEC’s current thinking on liquid staking.
The Cross-Chain Giant Set for 1,000%+ Gains
As crypto markets surge, one multi-chain financial protocol is being targeted for massive institutional investment before retail discovers it.
Its transaction volume is skyrocketing across all major blockchains while its price remains suppressed as retail has yet to discover it – creating a coiled spring ready to release.
Palantir Surges Past $1B Quarter
Palantir Technologies just reported its first-ever billion-dollar quarter, driven by soaring demand for artificial intelligence. Revenue jumped 48% year over year to $1 billion, with U.S. sales up 68%, and domestic commercial revenue surging 93%. Profit reached $327 million, up 33%, and the company raised its full-year guidance to $4.14–$4.15 billion.
CEO Alex Karp credited AI as the key driver, stating the technology is now embedded throughout Palantir’s operations—automating tasks and boosting productivity. The company plans to grow revenue while reducing headcount, already cutting its IT team by over 60%. Palantir’s “rule of 40” score hit a remarkable 94%, and executives say its custom AI tools are essential for real-world results. Karp emphasized that elite credentials don’t matter at Palantir—only performance does. Analysts remain bullish, with Bank of America reaffirming a buy rating. Karp also stressed AI’s role in American industry, saying, “This is an America story.”
🎁 START YOUR 30-DAY FREE TRIAL NOW
👉 Start your free trial
Wegovy Sales Jump 67% YoY
Novo Nordisk reported strong second-quarter results, with total revenue rising 13% year-over-year to 76.86 billion Danish kroner ($11.92 billion), slightly beating forecasts. Sales of its flagship weight-loss drug Wegovy surged 67% to 19.53 billion kroner, just below analyst expectations. Net profit for the quarter came in at 26.5 billion kroner, roughly in line with projections.
Despite the solid numbers, the company reaffirmed its full-year guidance, which had been lowered last week due to slower expected growth for Wegovy and Ozempic in the U.S. Novo now forecasts annual sales growth of 8% to 14% and operating profit growth of 10% to 16%. The company also pledged cost-cutting and more focused commercial execution after its share price fell sharply following the revised outlook.
Outgoing CEO Lars Fruergaard Jørgensen emphasized continued investment in future growth, while incoming CEO Maziar Mike Doustdar promised urgent, high-performance leadership aimed at pushing Novo Nordisk to new heights.
DISCLAIMER: None of this is financial advice. This newsletter is strictly educational and is not investment advice or a solicitation to buy or sell any assets or to make any financial decisions. Please be careful and do your own research.